Evidence of inflammatory system involvement in Parkinson's disease

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Chao, Yinxia ^a,b   Wong, Siew Cheng ^c,d   Tan, Eng King ^a,b,e  

^a NATIONAL NEUROSCIENCE INSTITUTE   (Singapore)

^b DUKE NUS MEDICAL SCHOOL   (Singapore)

^c AGENCY FOR SCIENCE   (Singapore)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^e SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; GAMMA INTERFERON; GLUTAMIC ACID; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; LEVODOPA; MINOCYCLINE; NALOXONE; NITRIC OXIDE; PATTERN RECOGNITION RECEPTOR; REACTIVE OXYGEN METABOLITE; STROMELYSIN; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 7; TUMOR NECROSIS FACTOR ALPHA; AUTACOID;

ARTICLE; B LYMPHOCYTE; BLOOD BRAIN BARRIER; CELL INFILTRATION; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; IN VIVO STUDY; INFECTION; INNATE IMMUNITY; LEUKOCYTE; MESENCHYMAL STEM CELL; MICROGLIA; NATURAL KILLER CELL; NEURAL STEM CELL; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PATHOPHYSIOLOGY; STEM CELL TRANSPLANTATION; T LYMPHOCYTE; UPREGULATION; COMMUNICABLE DISEASES; COMPLICATION; IMMUNOLOGY; INFLAMMATION; METABOLISM; PATHOLOGY;

COMMUNICABLE DISEASES; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MICROGLIA; PARKINSON DISEASE;

EID: 84904106826     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/308654     Document Type: Article

References (117)

1. Dauer W., Przedborski S., Parkinson's disease: mechanisms and models. Neuron 2003 39 6 889 909 10.1016/S0896-6273(03)00568-3 2-s2.0-0141741347 (Pubitemid 37130207)
2. Członkowska A., Kurkowska-Jastrzebska I., Członkowski A., Peter D., Stefano G. B., Immune processes in the pathogenesis of Parkinson's disease-a potential role for microglia and nitric oxide. Medical Science Monitor 2002 8 8 RA165 RA177 (Pubitemid 34951437)
3. Whitton P. S., Inflammation as a causative factor in the aetiology of Parkinson's disease. British Journal of Pharmacology 2007 150 8 963 976 10.1038/sj.bjp.0707167 2-s2.0-34247366072 (Pubitemid 46628616)
4. Kim D. K., Kim H. S., Kim A., Kim J. H., Kim B., Noh G., Beaven M. A., Kim Y. M., Choi W. S., DJ-1 regulates mast cell activation and IgE-mediated allergic responses. Journal of Allergy and Clinical Immunology 2013 131 6 1653 1662 10.1016/j.jaci.2012.10.012 2-s2.0-84878615032
5. Manzanillo P. S., Ayres J. S., Watson R. O., Collins A. C., Souza G., Rae C. S., Schneider D. S., Nakamura K., Shiloh M. U., Cox J. S., The ubiquitin ligase parkin mediates resistance to intracellular pathogens. Nature 2013 501 7468 512 516 10.1038/nature12566 2-s2.0-84883211938
6. Deleidi M., Hallett P. J., Koprich J. B., Chung C., Isacson O., The toll-like receptor-3 agonist polyinosinic:polycytidylic acid triggers nigrostriatal dopaminergic degeneration. Journal of Neuroscience 2010 30 48 16091 16101 10.1523/JNEUROSCI.2400-10.2010 2-s2.0-78649745833
7. Qin L., Liu Y., Hong J., Crews F. T., NADPH oxidase and aging drive microglial activation, oxidative stress, and dopaminergic neurodegeneration following systemic LPS administration. GLIA 2013 61 6 855 868 10.1002/glia.22479 2-s2.0-84876463910
8. Tanji K., Mori F., Imaizumi T., Yoshida H., Matsumiya T., Tamo W., Yoshimoto M., Odagiri H., Sasaki M., Takahashi H., Satoh K., Wakabayashi K., Upregulation of α -synuclein by lipopolysaccharide and interleukin-1 in human macrophages. Pathology International 2002 52 9 572 577 10.1046/j.1440-1827.2002.01385.x 2-s2.0-18744395468 (Pubitemid 35335039)
9. Russo I., Bubacco L., Greggio E., LRRK2 and neuroinflammation: partners in crime in Parkinson's disease? Journal of Neuroinflammation 2014 11, article 52 10.1186/1742-2094-11-52
10. Brodacki B., Staszewski J., Toczyłowska B., Kozłowska E., Drela N., Chalimoniuk M., Stepien A., Serum interleukin (IL-2, IL-10, IL-6, IL-4), TNF α and INF γ concentrations are elevated in patients with atypical and idiopathic parkinsonism. Neuroscience Letters 2008 441 2 158 162 10.1016/j.neulet.2008.06.040 2-s2.0-46749085399
11. Reale M., Greig N. H., Kamal M. A., Peripheral chemo-cytokine profiles in Alzheimer's and Parkinson's diseases. Mini-Reviews in Medicinal Chemistry 2009 9 10 1229 1241 10.2174/138955709789055199 2-s2.0-70450213422
12. Song I. U., Kim J. S., Chung S. W., Lee K. S., Is there an association between the level of high-sensitivity C-reactive protein and idiopathic parkinson's disease? A comparison of parkinson's disease patients, disease controls and healthy individuals. European Neurology 2009 62 2 99 104 10.1159/000222780 2-s2.0-66749129095
13. Mogi M., Harada M., Kondob T., Riederer P., Inagaki H., Minami M., Nagatsu T., Interleukin-1 β interleukin-6, epidermal growth factor and transforming growth factor- α are elevated in the brain from parkinsonian patients. Neuroscience Letters 1994 180 2 147 150 10.1016/0304-3940(94)90508-8 2-s2.0-0028171374
14. 2-microglobulin levels are elevated in the striatum in Parkinson's diseaselevels are elevated in the striatum in Parkinson's disease. Journal of Neural Transmission: Parkinson's Disease and Dementia Section 1995 9 1 87 92 10.1007/BF02252965 2-s2.0-0028986551
15. Blum-Degen D., Müller T., Kuhn W., Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neuroscience Letters 1995 202 17 20 10.1016/0304-3940(95)12192-7
16. Mount M. P., Lira A., Grimes D., Smith P. D., Faucher S., Slack R., Anisman H., Hayley S., Park D. S., Involvement of interferon- γ in microglial-mediated loss of dopaminergic neurons. Journal of Neuroscience 2007 27 12 3328 3337 10.1523/JNEUROSCI.5321-06.2007 2-s2.0-33947515418 (Pubitemid 46474138)
17. Kim E., Hwang O., Role of matrix metalloproteinase-3 in neurodegeneration. Journal of Neurochemistry 2011 116 1 22 32 10.1111/j.1471-4159.2010.07082.x 2-s2.0-78650099684
18. Chung Y. C., Kim Y., Bok E., Yune T. Y., Maeng S., Jin B. K., MMP-3 contributes to nigrostriatal dopaminergic neuronal loss, BBB damage, and neuroinflammation in an MPTP mouse model of Parkinson's disease. Mediators of Inflammation 2013 2013 11 370526 10.1155/2013/370526 2-s2.0-84880273031
19. Yamada S., Nagai T., Nakai T., Matrix metalloproteinase-3 is a possible mediator of neurodevelopmental impairment due to polyI: C-induced innate immune activation of astrocytes. Brain, Behavior, and Immunity 2014 38 272 282 10.1016/j.bbi.2014.02.014
20. Fagundes C. T., Costa V. V., Cisalpino D., Amaral F. A., Souza P. R. S., Souza R. S., Ryffel B., Vieira L. Q., Silva T. A., Atrasheuskaya A., Ignatyev G., Sousa L. P., Souza D. G., Teixeira M. M., IFN- γ production depends on IL-12 and IL-18 combined action and mediates host resistance to dengue virus infection in a nitric oxide-dependent manner. PLoS Neglected Tropical Diseases 2011 5 12, article e1449 10.1371/journal.pntd.0001449 2-s2.0-84855283930
21. Kannan Y., Yu J., Raices R. M., Seshadri S., Wei M., Caligiuri M. A., Wewers M. D., I B ζ augments IL-12- and IL-18-mediated IFN- γ production in human NK cells. Blood 2011 117 10 2855 2863 10.1182/blood-2010-07- 294702 2-s2.0-79953078552
22. Takahashi H. K., Iwagaki H., Hamano R., Wake H., Kanke T., Liu K., Yoshino T., Tanaka N., Nishibori M., Effects of adenosine on adhesion molecule expression and cytokine production in human PBMC depend on the receptor subtype activated. British Journal of Pharmacology 2007 150 6 816 822 10.1038/sj.bjp.0707126 2-s2.0-33947324677 (Pubitemid 46440211)
23. Gillett A., Hedreul M. T., Khademi M., Espinosa A., Beyeen A. D., Jagodic M., Kockum I., Harris R. A., Olsson T., Interleukin 18 receptor 1 expression distinguishes patients with multiple sclerosis. Multiple Sclerosis 2010 16 9 1056 1065 10.1177/1352458510364634 2-s2.0-77956307587
24. Millward J. M., Løbner M., Wheeler R. D., Owens T., Inflammation in the central nervous system and Th17 responses are inhibited by IFN- γ -induced IL-18 binding protein. The Journal of Immunology 2010 185 4 2458 2466 10.4049/jimmunol.0902153 2-s2.0-77956897473
25. Celik S. K., Öz Z. S., Dursun A., Interleukin 18 gene polymorphism is a risk factor for multiple sclerosis. Molecular Biology Reports 2014 41 3 1653 1658 10.1007/s11033-013-3013-5
26. Sugama S., Wirz S. A., Barr A. M., Conti B., Bartfai T., Shibasaki T., Interleukin-18 null mice show diminished microglial activation and reduced dopaminergic neuron loss following acute 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine treatment. Neuroscience 2004 128 2 451 458 10.1016/j.neuroscience.2004.07.020 2-s2.0-4444333135 (Pubitemid 39200490)
27. Xu X., Li D., He Q., Gao J., Chen B., Xie A., Interleukin-18 promoter polymorphisms and risk of Parkinson's disease in a Han Chinese population. Brain Research 2011 1381 90 94 10.1016/j.brainres.2011.01.025 2-s2.0-79952280281
28. Nie K., Zhang Y., Gan R., Wang L., Zhao J., Huang Z., Tang H., Wang L., Polymorphisms in immune/inflammatory cytokine genes are related to Parkinson's disease with cognitive impairment in the Han Chinese population. Neuroscience Letters 2013 541 111 115 10.1016/j.neulet.2013.02.024 2-s2.0-84876407781
29. Yamada T., McGeer P. L., McGeer E. G., Lewy bodies in Parkinson's disease are recognized by antibodies to complement proteins. Acta Neuropathologica 1992 84 1 100 104 10.1007/BF00427222 2-s2.0-0026680616
30. Koziorowski D., Tomasiuk R., Szlufik S., Friedman A., Inflammatory cytokines and NT-proCNP in Parkinson's disease patients. Cytokine 2012 60 3 762 766 10.1016/j.cyto.2012.07.030 2-s2.0-84867985183
31. Béraud D., Hathaway H. A., Trecki J., Chasovskikh S., Johnson D. A., Johnson J. A., Federoff H. J., Shimoji M., Mhyre T. R., Maguire-Zeiss K. A., Microglial activation and antioxidant responses induced by the Parkinson's disease protein α -synuclein. Journal of Neuroimmune Pharmacology 2013 8 1 94 117 10.1007/s11481-012-9401-0 2-s2.0-84874654334
32. Iwamura C., Nakayama T., Toll-like receptors in the respiratory system: their roles in inflammation. Current Allergy and Asthma Reports 2008 8 1 7 13 10.1007/s11882-008-0003-0 2-s2.0-41549134095 (Pubitemid 351459687)
33. Cario E., Toll-like receptors in inflammatory bowel diseases: a decade later. Inflammatory Bowel Diseases 2010 16 9 1583 1597 10.1002/ibd.21282 2-s2.0-77956289824
34. Seneviratne A. N., Sivagurunathan B., Monaco C., Toll-like receptors and macrophage activation in atherosclerosis. Clinica Chimica Acta 2012 413 1-2 3 14 10.1016/j.cca.2011.08.021 2-s2.0-82955178219
35. Brudek T., Winge K., Agander T. K., Pakkenberg B., Screening of toll-like receptors expression in multiple system atrophy brains. Neurochemical Research 2013 38 6 1252 1259 10.1007/s11064-013-1020-5 2-s2.0-84878011295
36. Roodveldt C., Labrador-Garrido A., Gonzalez-Rey E., Preconditioning of microglia by α -synuclein strongly affects the response induced by toll-like receptor (TLR) stimulation. PLoS ONE 2013 8 11 e79160
37. Saresella M., Marventano I., Calabrese E., Piancone F., Rainone V., Gatti A., Alberoni M., Nemni R., Clerici M., A complex proinflammatory role for peripheral monocytes in Alzheimer's disease. Journal of Alzheimer's Disease 2014 38 2 403 413 10.3233/JAD-131160
38. Hafner-Bratkovič I., Benčina M., Fitzgerald K. A., Golenbock D., Jerala R., NLRP3 inflammasome activation in macrophage cell lines by prion protein fibrils as the source of IL-1 β and neuronal toxicity. Cellular and Molecular Life Sciences 2012 69 24 4215 4228 10.1007/s00018-012- 1140-0 2-s2.0-84870705290
39. Schnaars M., Beckert H., Halle A., Assessing β -amyloid-induced NLRP3 inflammasome activation in primary microglia. Methods in Molecular Biology 2013 1040 1 8 10.1007/978-1-62703-523-1-1 2-s2.0-84880491311
40. Tan M., Yu J., Jiang T., Zhu X., Tan L., The NLRP3 inflammasome in Alzheimer's disease. Molecular Neurobiology 2013 48 3 875 882 10.1007/s12035-013-8475-x 2-s2.0-84877788915
41. Meng X. F., Wang X. L., Tian X. J., Nod-like receptor protein 1 inflammasome mediates neuron injury under high glucose. Molecular Neurobiology 2014 49 2 673 684
42. Devine M. J., Kaganovich A., Ryten M., Mamais A., Trabzuni D., Manzoni C., McGoldrick P., Chan D., Dillman A., Zerle J., Horan S., Taanman J., Hardy J., Marti-Masso J., Healey D., Schapira A. H., Wolozin B., Bandopadhyay R., Cookson M. R., van der Brug M. P., Lewis P. A., Pathogenic LRRK2 mutations do not alter gene expression in cell model systems or human brain tissue. PLoS ONE 2011 6 7 e22489 10.1371/journal.pone.0022489 2-s2.0-79960677581
43. Ohta A., Sitkovsky M., Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 2001 414 6866 916 920 10.1038/414916a 2-s2.0-0035924320 (Pubitemid 34024743)
44. Saha N., Moldovan F., Tardif G., Interleukin-1 β -converting enzyme (caspase-1) in human osteoarthritic tissues. Localization and role in the maturation of interleukin-1 β and interleukin-18. Arthritis & Rheumatism 1999 42 8 1577 1587 (Pubitemid 30263623)
45. Sullivan G. W., Adenosine A2A receptor agonists as anti-inflammatory agents. Current Opinion in Investigational Drugs 2003 4 11 1313 1319 2-s2.0-0347093665 (Pubitemid 38100576)
46. Yamagata T., Ichinose M., Agents against cytokine synthesis or receptors. European Journal of Pharmacology 2006 533 1-3 289 301 10.1016/j.ejphar.2005.12. 046 2-s2.0-33644755474 (Pubitemid 43340020)
47. 2A adenosine receptors that are antiinflammatory when stimulated. European Journal of Immunology 2013 43 8 2206 2216 10.1002/eji.201343314 2-s2.0-84881501350
48. Burnstock G., Fredholm B. B., Verkhratsky A., Adenosine and ATP receptors in the brain. Current Topics in Medicinal Chemistry 2011 11 8 973 1011 10.2174/156802611795347627 2-s2.0-79954452804
49. Casetta I., Vincenzi F., Bencivelli D., Corciulo C., Gentile M., Granieri E., Borea P. A., Varani K., A2A adenosine receptors and Parkinson's disease severity. Acta Neurologica Scandinavica 2014 129 4 276 281 10.1111/ane.12181 2-s2.0-84883163151
50. Khanapur S., Waarde A. V., Ishiwata K., Adenosine A2A receptor Antagonists as Positron Emission Tomography (PET) Tracers. Current Medicinal Chemistry 2013 21 3 312 328
51. Fox S. H., Non-dopaminergic treatments for motor control in Parkinson's disease. Drugs 2013 73 13 1405 1415 10.1007/s40265-013-0105-4
52. Chao Y. X., He B. P., Tay S. S., Mesenchymal stem cell transplantation attenuates blood brain barrier damage and neuroinflammation and protects dopaminergic neurons against MPTP toxicity in the substantia nigra in a model of Parkinson's disease. Journal of Neuroimmunology 2009 216 1-2 39 50 10.1016/j.jneuroim.2009.09.003 2-s2.0-71749083461
53. Prineas J. W., Parratt J. D. E., Oligodendrocytes and the early multiple sclerosis lesion. Annals of Neurology 2012 72 1 18 31 10.1002/ana.23634 2-s2.0-84864434405
54. Zhou Y., Wang Y., Kovacs M., Jin J., Zhang J., Microglial activation induced by neurodegeneration: a proteomic analysis. Molecular and Cellular Proteomics 2005 4 10 1471 1479 10.1074/mcp.M500114-MCP200 2-s2.0-27644559809 (Pubitemid 41555473)
55. Smeyne M., Jiao Y., Shepherd K. R., Smeyne R. J., Glia cell number modulates sensitivity to MPTP in mice. Glia 2005 52 2 144 152 10.1002/glia.20233 2-s2.0-27844536914 (Pubitemid 41652918)
56. Sawada M., Imamura K., Nagatsu T., Role of cytokines in inflammatory process in Parkinson's disease. Journal of Neural Transmission, Supplement 2006 70 373 381 2-s2.0-33750373343 (Pubitemid 44622226)
57. McGeer P. L., Itagaki S., Boyes B. E., McGeer E. G., Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988 38 8 1285 1291 10.1212/WNL.38.8.1285 2-s2.0-0023789193
58. 11C(R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiology of Disease 2006 21 2 404 412 10.1016/j.nbd.2005.08.002 2-s2.0-30744472146 (Pubitemid 43099863)
59. Członkowska A., Kohutnicka M., Kurkowska-Jastrzbska I., Członkowski A., Microglial reaction in MPTP (1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine) induced Parkinson's disease mice model. Neurodegeneration 1996 5 2 137 143 10.1006/neur.1996.0020 2-s2.0-0030175757 (Pubitemid 26248603)
60. Kohutnicka M., Lewandowska E., Kurkowska-Jastrzebska I., Członkowski A., Członkowska A., Microglial and astrocytic involvement in a murine model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Immunopharmacology 1998 39 3 167 180 10.1016/S0162-3109(98)00022-8 2-s2.0-0032100191 (Pubitemid 28432061)
61. Lee Mosley R., Benner E. J., Kadiu I., Thomas M., Boska M. D., Hasan K., Laurie C., Gendelman H. E., Neuroinflammation, oxidative stress, and the pathogenesis of Parkinson's disease. Clinical Neuroscience Research 2006 6 5 261 281 10.1016/j.cnr.2006.09.006 2-s2.0-33845211714 (Pubitemid 44849177)
62. Langston J. W., Forno L. S., Tetrud J., Reeves A. G., Kaplan J. A., Karluk D., Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Annals of Neurology 1999 46 4 598 605 (Pubitemid 29466438)
63. Hamza T. H., Zabetian C. P., Tenesa A., Laederach A., Montimurro J., Yearout D., Kay D. M., Doheny K. F., Paschall J., Pugh E., Kusel V. I., Collura R., Roberts J., Griffith A., Samii A., Scott W. K., Nutt J., Factor S. A., Payami H., Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease. Nature Genetics 2010 42 9 781 785 10.1038/ng.642 2-s2.0-77956646167
64. Chock V. Y., Giffard R. G., Development of neonatal murine microglia In vitro: changes in response to lipopolysaccharide and ischemia-like injury. Pediatric Research 2005 57 4 475 480 10.1203/01.PDR.0000155758.79523.44 2-s2.0-15244339431 (Pubitemid 40389333)
65. Lee M., Neurotransmitters and microglial-mediated neuroinflammation. Current Protein and Peptide Science 2013 14 1 21 32 10.2174/1389203711314010005 2-s2.0-84876741388
66. Pais T. F., Szeg É. M., Marques O., Miller-Fleming L., Antas P., Guerreiro P., de Oliveira R. M., Kasapoglu B., Outeiro T. F., The NAD-dependent deacetylase sirtuin 2 is a suppressor of microglial activation and brain inflammation. EMBO Journal 2013 32 19 2603 2616 10.1038/emboj.2013.200 2-s2.0-84883447080
67. Mclaughlin P., Zhou Y., Ma T., Liu J., Zhang W., Hong J., Kovacs M., Zhang J., Proteomic analysis of microglial contribution to mouse strain-dependent dopaminergic neurotoxicity. Glia 2006 53 6 567 582 10.1002/glia.20294 2-s2.0-33646011523
68. de Lella Ezcurra A. L., Chertoff M., Ferrari C., Graciarena M., Pitossi F., Chronic expression of low levels of tumor necrosis factor- α in the substantia nigra elicits progressive neurodegeneration, delayed motor symptoms and microglia/macrophage activation. Neurobiology of Disease 2010 37 3 630 640 10.1016/j.nbd.2009.11.018 2-s2.0-75949102620
69. Mogi M., Harada M., Narabayashi H., Inagaki H., Minami M., Nagatsu T., Interleukin (IL)-1 β IL-2, IL-4, IL-6 and transforming growth factor- α levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease. Neuroscience Letters 1996 211 1 13 16 10.1016/0304-3940(96)12706-3 2-s2.0-0030582991 (Pubitemid 26228016)
70. Ferrari C. C., Pott Godoy M. C., Tarelli R., Chertoff M., Depino A. M., Pitossi F. J., Progressive neurodegeneration and motor disabilities induced by chronic expression of IL-1 β in the substantia nigra. Neurobiology of Disease 2006 24 1 183 193 10.1016/j.nbd.2006.06.013 2-s2.0-33748973074 (Pubitemid 44437611)
71. Godoy M. C. P., Tarelli R., Ferrari C. C., Sarchi M. I., Pitossi F. J., Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson's disease. Brain 2008 131, part 7 1880 1894 10.1093/brain/awn101 2-s2.0-46849088998 (Pubitemid 351957456)
72. Gordon R., Anantharam V., Kanthasamy A. G., Proteolytic activation of proapoptotic kinase protein kinase C δ by tumor necrosis factor α death receptor signaling in dopaminergic neurons during neuroinflammation. Journal of Neuroinflammation 2012 9 article 82 10.1186/1742-2094-9-82 2-s2.0-84862208552
73. Sriram K., Matheson J. M., Benkovic S. A., Miller D. B., Luster M. I., O'Callaghan J. P., Deficiency of TNF receptors suppresses microglial activation and alters the susceptibility of brain regions to MPTP-induced neurotoxicity: role of TNF- α 1. FASEB Journal 2006 20 6 670 682 10.1096/fj.05-5106com 2-s2.0-33646255922 (Pubitemid 44933311)
74. Stone D. K., Reynolds A. D., Mosley R. L., Gendelman H. E., Innate and adaptive immunity for the pathobiology of Parkinson's disease. Antioxidants and Redox Signaling 2009 11 9 2151 2166 10.1089/ars.2009.2460 2-s2.0-68249145501
75. Appel S. H., Beers D. R., Henkel J. S., T cell-microglial dialogue in Parkinson's disease and amyotrophic lateral sclerosis: are we listening? Trends in Immunology 2010 31 1 7 17 10.1016/j.it.2009.09.003 2-s2.0-73149116008
76. Harm A. S., Cao S., Rowse A. L., Thome A. D., Li X., Mangieri L. R., Cron R. Q., Shacka J. J., Raman C., Standaert D. G., MHCII is required for α -synuclein-induced activation of microglia, CD4 T cell proliferation, and dopaminergic neurodegeneration. Journal of Neuroscience 2013 33 23 9592 9600 10.1523/JNEUROSCI.5610-12.2013 2-s2.0-84878508881
77. Michelucci A., Heurtaux T., Grandbarbe L., Morga E., Heuschling P., Characterization of the microglial phenotype under specific pro-inflammatory and anti-inflammatory conditions: effects of oligomeric and fibrillar amyloid- β Journal of Neuroimmunology 2009 210 1-2 3 12 10.1016/j.jneuroim.2009.02. 003 2-s2.0-67349251479
78. Engelhardt B., The blood-central nervous system barriers actively control immune cell entry into the central nervous system. Current Pharmaceutical Design 2008 14 16 1555 1565 10.2174/138161208784705432 2-s2.0-48949117580 (Pubitemid 352002983)
79. Alvarez J. I., Dodelet-Devillers A., Kebir H., Ifergan I., Fabre P. J., Terouz S., Sabbagh M., Wosik K., Bourbonnière L., Bernard M., Van Horssen J., De Vries H. E., Charron F., Prat A., The Hedgehog pathway promotes blood-brain barrier integrity and CNS immune quiescence. Science 2011 334 6063 1727 1731 10.1126/science.1206936 2-s2.0-84455205524
80. McGeer P. L., Kawamata T., Walker D. G., Akiyama H., Tooyama I., McGeer E. G., Microglia in degenerative neurological disease. Glia 1993 7 1 84 92 10.1002/glia.440070114 2-s2.0-0027354835
81. + lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. Journal of Clinical Investigation 2009 119 1 182 192 10.1172/JCI36470 2-s2.0-58849107919
82. Tufekci K. U., Genc S., Genc K., The endotoxin-induced neuroinflammation model of Parkinson's disease. Parkinson's Disease 2011 2011 25 487450 10.4061/2011/487450 2-s2.0-79952157789
83. Reynolds A. D., Banerjee R., Liu J., Gendelman H. E., Mosley R. L., Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson's disease. Journal of Leukocyte Biology 2007 82 5 1083 1094 10.1189/jlb.0507296 2-s2.0-36249032567 (Pubitemid 350133504)
84. Reynolds A. D., Stone D. K., Hutter J. A. L., Benner E. J., Mosley R. L., Gendelman H. E., Regulatory T cells attenuate Th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson's disease. Journal of Immunology 2010 184 5 2261 2271 10.4049/jimmunol.0901852 2-s2.0-77951882307
85. Bartels A. L., Willemsen A. T. M., Kortekaas R., De Jong B. M., De Vries R., De Klerk O., Van Oostrom J. C. H., Portman A., Leenders K. L., Decreased blood-brain barrier P-glycoprotein function in the progression of Parkinson's disease, PSP and MSA. Journal of Neural Transmission 2008 115 7 1001 1009 10.1007/s00702-008-0030-y 2-s2.0-46649085260
86. Appay V., Rowland-Jones S. L., RANTES: a versatile and controversial chemokine. Trends in Immunology 2001 22 2 83 87 10.1016/S1471-4906(00)01812-3 2-s2.0-0034918334 (Pubitemid 32667526)
87. Rentzos M., Nikolaou C., Andreadou E., Paraskevas G. P., Rombos A., Zoga M., Tsoutsou A., Boufidou F., Kapaki E., Vassilopoulos D., Circulating interleukin-15 and RANTES chemokine in Parkinson's disease. Acta Neurologica Scandinavica 2007 116 6 374 379 10.1111/j.1600-0404.2007.00894.x 2-s2.0-35748932913 (Pubitemid 350045501)
88. Stevens C. H., Rowe D., Morel-Kopp M., Orr C., Russell T., Ranola M., Ward C., Halliday G. M., Reduced T helper and B lymphocytes in Parkinson's disease. Journal of Neuroimmunology 2012 252 1-2 95 99 10.1016/j.jneuroim.2012. 07.015 2-s2.0-84867140349
89. Niwa F., Kuriyama N., Nakagawa M., Imanishi J., Effects of peripheral lymphocyte subpopulations and the clinical correlation with Parkinson's disease. Geriatrics and Gerontology International 2012 12 1 102 107 10.1111/j.1447-0594. 2011.00740.x 2-s2.0-84155195212
90. Funk N., Wieghofer P., Grimm S., Schaefer R., Bühring H., Gasser T., Biskup S., Characterization of peripheral hematopoietic stem cells and monocytes in Parkinson's disease. Movement Disorders 2013 28 3 392 395 10.1002/mds.25300 2-s2.0-84875552430
91. Shin E. C., Cho S. E., Lee D., Hur M., Paik S. R., Park J. H., Kim J., Expression patterns of α -synuclein in human hematopoietic cells and in Drosophila at different developmental stages. Molecules and Cells 2000 10 1 65 70 10.1007/s10059-000-0065-x 2-s2.0-0034728281
92. Su A. I., Wiltshire T., Batalov S., Lapp H., Ching K. A., Block D., Zhang J., Soden R., Hayakawa M., Kreiman G., Cooke M. P., Walker J. R., Hogenesch J. B., A gene atlas of the mouse and human protein-encoding transcriptomes. Proceedings of the National Academy of Sciences of the United States of America 2004 101 16 6062 6067 10.1073/pnas.0400782101 2-s2.0-11144358198 (Pubitemid 38520528)
93. Austin S. A., Floden A. M., Murphy E. J., Combs C. K., α -synuclein expression modulates microglial activation phenotype. Journal of Neuroscience 2006 26 41 10558 10563 10.1523/JNEUROSCI.1799-06.2006 2-s2.0-33749836242 (Pubitemid 44564607)
94. Wu C., Orozco C., Boyer J., Leglise M., Goodale J., Batalov S., Hodge C. L., Haase J., Janes J., Huss J. W. III, Su A. I., BioGPS: an extensible and customizable portal for querying and organizing gene annotation resources. Genome Biology 2009 10 11, article R130 10.1186/gb-2009-10-11-r130 2-s2.0-76249090489
95. Cardoso C. C., Pereira A. C., de Sales Marques C., Moraes M. O., Leprosy susceptibility: genetic variations regulate innate and adaptive immunity, and disease outcome. Future Microbiology 2011 6 5 533 549 10.2217/fmb.11.39 2-s2.0-79956078781
96. Trabzuni D., Ryten M., Emmett W., Ramasamy A., Lackner K. J., Zeller T., Walker R., Smith C., Lewis P. A., Mamais A., de Silva R., Vandrovcova J., Hernandez D., Nalls M. A., Sharma M., Garnier S., Lesage S., Simon-Sanchez J., Gasser T., Heutink P., Brice A., Singleton A., Cai H., Schadt E., Wood N. W., Bandopadhyay R., Weale M. E., Hardy J., Plagnol V., Fine-mapping, gene expression and splicing analysis of the disease associated LRRK2 locus. PLoS ONE 2013 8 8 e70724 10.1371/journal.pone.0070724 2-s2.0-84881484502
97. Hirotani M., Maita C., Niino M., Iguchi-Ariga S. M., Hamada S., Ariga H., Sasaki H., Correlation between DJ-1 levels in the cerebrospinal fluid and the progression of disabilities in multiple sclerosis patients. Multiple Sclerosis 2008 14 8 1056 1060 10.1177/1352458508093616 2-s2.0-58149340184
98. Semchuk K. M., Love E. J., Lee R. G., Parkinson's disease: a test of the multifactorial etiologic hypothesis. Neurology 1993 43 6 1173 1180 10.1212/WNL.43.6.1173 2-s2.0-0027256104 (Pubitemid 23177719)
99. Vlajinac H., Dzoljic E., Maksimovic J., Marinkovic J., Sipetic S., Kostic V., Infections as a risk factor for Parkinson's disease: a case-control study. International Journal of Neuroscience 2013 123 5 329 332 10.3109/00207454.2012. 760560 2-s2.0-84876382325
100. Tomé C. M. L., Tyson T., Rey N. L., Grathwohl S., Britschgi M., Brundin P., Inflammation and α -synuclein's prion-like behavior in Parkinson's disease-is there a link? Molecular Neurobiology 2013 47 2 561 574 10.1007/s12035-012-8267-8
101. Olanow C. W., Brundin P., Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder? Movement Disorders 2013 28 1 31 40 10.1002/mds.25373 2-s2.0-84873458538
102. Lee C. S., Won C., Yoo H., Yi E. H., Cho Y., Maeng J. W., Sung S. H., Ye S., Chung M., Inhibition of double-stranded RNA-induced inducible nitric oxide synthase expression by fraxinellone and sauchinone in murine microglia. Biological and Pharmaceutical Bulletin 2009 32 11 1870 1874 10.1248/bpb.32.1870 2-s2.0-70350731120
103. Ha D., Stone D. K., Mosley R. L., Gendelman H. E., Immunization strategies for Parkinson's disease. Parkinsonism and Related Disorders 2012 18 1 S218 S221 2-s2.0-84858614537
104. McCoy M. K., Ruhn K. A., Martinez T. N., McAlpine F. E., Blesch A., Tansey M. G., Intranigral lentiviral delivery of dominant-negative TNF attenuates neurodegeneration and behavioral deficits in hemiparkinsonian rats. Molecular Therapy 2008 16 9 1572 1579 10.1038/mt.2008.146 2-s2.0-50549103590
105. Harms A. S., Barnum C. J., Ruhn K. A., Varghese S., Trevĩo I., Blesch A., Tansey M. G., Delayed dominant-negative TNF gene therapy halts progressive loss of nigral dopaminergic neurons in a rat model of parkinson's disease. Molecular Therapy 2011 19 1 46 52 10.1038/mt.2010.217 2-s2.0-78650880194
106. Chen H., Zhang S. M., Hernán M. A., Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Archives of Neurology 2003 60 8 1059 1064 10.1001/archneur.60.8.1059 (Pubitemid 36975791)
107. Etminan M., Carleton B. C., Samii A., Non-steroidal anti-inflammatory drug use and the risk of Parkinson disease: a retrospective cohort study. Journal of Clinical Neuroscience 2008 15 5 576 577 10.1016/j.jocn.2007.02.095 2-s2.0-41549133855
108. Samii A., Etminan M., Wiens M. O., Jafari S., NSAID use and the risk of parkinsons disease: systematic review and meta-analysis of observational studies. Drugs & Aging 2009 26 9 769 779 10.2165/11316780-000000000-00000 2-s2.0-69949164871
109. Gao X., Chen H., Schwarzschild M. A., Ascherio A., Use of ibuprofen and risk of Parkinson disease. Neurology 2011 76 10 863 869 10.1212/WNL. 0b013e31820f2d79 2-s2.0-79952941281
110. Liu B., Du L., Hong J. S., Naloxone protects rat dopaminergic neurons against inflammatory damage through inhibition of microglia activation and superoxide generation. The Journal of Pharmacology and Experimental Therapeutics 2000 293 2 607 617 2-s2.0-0034015558 (Pubitemid 30244114)
111. Castaño A., Herrera A. J., Cano J., Machado A., The degenerative effect of a single intranigral injection of LPS on the dopaminergic system is prevented by dexamethasone, and not mimicked by rh-TNF- α IL-1 β IFN- γ Journal of Neurochemistry 2002 81 1 150 157 10.1046/j.1471-4159.2002. 00799.x 2-s2.0-0036077851 (Pubitemid 34808862)
112. Kim H., Suh Y., Minocycline and neurodegenerative diseases. Behavioural Brain Research 2009 196 2 168 179 10.1016/j.bbr.2008.09.040 2-s2.0-57549088119
113. Lu L., Li F., Wang X., Novel anti-inflammatory and neuroprotective agents for Parkinson's disease. CNS and Neurological Disorders-Drug Targets 2010 9 2 232 240 10.2174/187152710791012035 2-s2.0-77949899785
114. Lee M., Tazzari V., Giustarini D., Rossi R., Sparatore A., Del Soldato P., McGeer E., McGeer P. L., Effects of hydrogen sulfide-releasing L-DOPA derivatives on glial activation: potential for treating Parkinson disease. The Journal of Biological Chemistry 2010 285 23 17318 17328 10.1074/jbc.M110.115261 2-s2.0-77952924546
115. Sánchez-Pernaute R., Ferree A., Cooper O., Yu M., Brownell A., Isacson O., Selective COX-2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson's disease. Journal of Neuroinflammation 2004 1 1, article 6 10.1186/1742-2094-1-6 2-s2.0-4344645719 (Pubitemid 39130328)
116. Teismann P., COX-2 in the neurodegenerative process of Parkinson's disease. BioFactors 2012 38 6 395 397 10.1002/biof.1035 2-s2.0-84871235128
117. Paul G., Anisimov S. V., The secretome of mesenchymal stem cells: potential implications for neuroregeneration. Biochimie 2013 95 12 2246 2256 10.1016/j.biochi.2013.07.013 2-s2.0-84880671209